Abbott's recent results show 7.6% organic revenue growth, driven by medical devices and pharmaceuticals, leading to raised full-year EPS guidance. Despite ongoing NEC baby formula lawsuits ...

Now, medical device companies, including north suburban-based Abbott Laboratories, are hoping health enthusiasts will embrace a new type of wellness accessory: wearable sensors to track glucose ...

Abbott Laboratories beat third-quarter profit and sales estimates on strong demand for its medical devices. Sales were also ...

Shares of Abbott rose 2% in afternoon trade. Increasing diabetes care awareness, wider insurance coverage and preference for devices that do not need finger pricks have benefited CGMs such as ...

Shares of Abbott rose 2% in afternoon trade. The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion ...

Abbott's medical devices unit generated $4.75 billion in sales for the third quarter, higher than analysts' average estimate ...

Sales growth in the medical devices segment drove Abbott Laboratories’ expectations-beating revenue in the past financial quarter as the company faces lower demand for COVID-19 tests ...

(Reuters) -Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for quarterly earnings on strong demand for its continuous glucose monitors ...